


Incorporating New Treatments Into the Management of B-Cell Malignancies


Learning Objectives

- Review the opportunities and challenges associated with the availability of new treatments for B-cell malignancies
- Learn about strategies, solutions, and resources for incorporating new treatments into clinical practice
- Review currently available treatment modalities for B-cell malignancies and the factors involved in clinical decision making

Navigating New Advances in Treatment Options for B-Cell Malignancies




Mature B-cell malignancies account for ~ 85% - 90% of NHL cases, and major subtypes include DLBCL (32%), CLL/SLL (19%), FL (17%), MZL (8%), and MCL (4%)^{1,2}



The treatment paradigm for these B-cell malignancies is rapidly evolving with the availability of newer targeted therapies and cellular immunotherapy, in addition to traditional approaches such as chemoimmunotherapy and stem cell transplantation³



Awareness and informed decision making are critical to improve patient outcomes when navigating the use of new therapeutics in B-cell malignancies³



Recent approvals of several targeted therapies for B-cell malignancies have rapidly expanded treatment options and improved standard of care, necessitating a renewed focus on treatment sequencing and clinical decision making across indications³

CLL/SLL, chronic lymphocytic leukemia/small lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; NHL, non-Hodgkin's lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma

1. Al-Hamadani M, et al. *Am J Hematol*. 2015;90(9):790-795. 2. Leukemia and Lymphoma Society. Accessed August 15th, 2023. <https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes>. 3. Flaherty C. Accessed August 2, 2023. <https://www.onclive.com/view/new-and-anticipated-advances-across-hematologic-malignancies-necessitate-improved-navigation-of-current-options>.

Awareness of New Treatments to Community Oncology is Complex



Community oncologists provide ~80% of cancer care in the US, treating a wide variety of malignancies¹

On any given day, community oncologists may manage multiple tumor types, creating unique challenges for integration of new treatments¹


The rapid development of new treatments including those for B-cell malignancies has led to a wealth of information and complicated the decision making process²

Navigating this complex landscape requires a proactive approach to new developments related to approvals, clinical practice guidelines, and reimbursement²

1. Wallis C. Accessed August 2, 2023. <https://www.scientificamerican.com/article/a-wave-of-new-cancer-treatments-challenges-community-oncologists-to-keep-up>.

2. Coggins J. Accessed August 2, 2023. <https://www.chiefhealthcareexecutive.com/view/community-oncologists-can-influence-the-future-of-oncology-with-advocacy-jonathan-coggins>.


Potential Barriers and Solutions for Incorporation of New Treatments in B-Cell Malignancies



CME, continuing medical education; IME, independent medical education.

1. Flaherty C. Accessed August 2, 2023. <https://www.onclive.com/view/new-and-anticipated-advances-across-hematologic-malignancies-necessitate-improved-navigation-of-current-options>. 2. Wallis C. Accessed August 2, 2023. <https://www.scientificamerican.com/article/a-wave-of-new-cancer-treatments-challenges-community-oncologists-to-keep-up>. 3. Patel K, Mukhi H. Accessed August 2, 2023. <https://www.targetedonc.com/view/incorporating-biomarker-testing-in-community-cancer-clinics-a-real-world-pilot-study>. 4. ASCO Daily News. Accessed August 15, 2023. <https://dailynews.ascopubs.org/do/podcast-challenges-oncologists-face-2023>. 5. Leick E. Accessed August 8, 2023. <https://www.onclive.com/view/community-oncologist-underscores-importance-of-education-and-collaboration>. 6. Ridgeway JL, et al. *Implement Sci Commun*. 2021;2(1):92. 7. Coggins J. Accessed August 2, 2023. <https://www.chiefhealthcareexecutive.com/view/community-oncologists-can-influence-the-future-of-oncology-with-advocacy-jonathan-coggins>.

Decision Making Criteria in the Treatment of B-Cell Malignancies




1. Jamil A, Mukkamalla SKR. In: StatPearls [Internet]. StatPearls Publishing; 2023. Accessed August 15, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK560826>. 2. Cheson BD, et al. *J Clin Oncol*. 2014;32(27):3059-3068. 3. Lumish M, et al. *J Hematol Oncol*. 2021;14(1):5. 4. Terret C, et al. *Expert Rev Hematol*. 2015;8(3):329-341. 5. InformedHealth.org. Accessed August 15, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK390308>. 6. Sun R, et al. *Mod Pathol*. 2016;29(10):1118-1142. 7. Ngu H, et al. *Am Soc Clin Oncol Educ Book*. 2022;42:1-14. 8. Loh KP, et al. *Blood Adv*. 2020;4(21):5492-5500.

The Role of Clinical Practice Guidelines in the Treatment of B-Cell Malignancies



- Evidence-based clinical practice guidelines, such as those established for B-cell malignancies are used across multiple practice settings to reduce variability and ensure quality treatment for all patients¹
- Clinical practice guidelines should be used as a tool to help physicians navigate very large bodies of data and make evidence-based decisions in an objective and time-efficient manner²
- Many clinical practice guidelines, including those for the treatment of B-cell malignancies are available online and offer subscription services that provide timely updates of recent clinical practice guidelines and educational resources³





1. InformedHealth.org. Accessed August 15, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK390308>.

2. Munteanu M, Burke J. Accessed August 7, 2023. <https://www.hmpgloballearningnetwork.com/site/jcp/article/barriers-lymphoma-clinical-practice-guideline-adherence-pilot-mixed-methods-research-study> 3. cdc.gov. Accessed August 15, 2023. <https://www.cdc.gov/csels/phio/clinical-guidelines/index.html>

Looking Beyond the Guidelines: Embracing Shared Patient Decision Making When Incorporating New Treatments



New **bi-directional** patient-centered view



In addition to clinical factors reflected in evidence-based guidelines, empowering patients when making healthcare decisions can improve overall quality of care^{1,2}

1. Loh KP, et al. *Blood Adv.* 2020;4(21):5492-5500. 2. Katz SJ, et al. *J Oncol Pract.* 2014;10(3):206-208.

Case Scenario: A New Treatment Is Approved for a Rare B-Cell Malignancy



“I just received an email alert for a newly approved treatment option for patients with a rare B-cell malignancy. I’m not sure if I will even see this type of patient in my practice, but I want to be prepared. Where should I start?”
– **Community Oncologist**

Helpful Steps and Considerations

- ✓ **Seek Education Resources** – research and attend upcoming continuing education sessions through professional societies or independent providers
- ✓ **Network and Collaborate** – establish and maintain relationships with academic oncologists and subspecialists involved directly in the trial
- ✓ **Connect With a Leading Cancer Center** – obtain new treatment education, access to genetic/biomarker testing, and referral to authorized treatment centers

Case Scenario: A Patient With a B-Cell Malignancy Relapsed Shortly After Standard of Care



“I treated a patient for a B-cell malignancy. It’s been less than 4 months since they received initial therapy, and they have already progressed. I’m not sure what to say to my patient and where to look for the best treatment options.”

– **Community Oncologist**

Helpful Steps and Considerations

- ✓ **Review Clinical Practice Guidelines** – review the latest disease-specific, evidence-based clinical guidelines for recommended treatment options
- ✓ **Consult With Subspecialists** – utilize professional societies and/or partnerships with leading cancer centers for help in case review and treatment selection
- ✓ **Advocacy Groups** – work with a patient advocacy group to better understand patient educational needs and financial assistance programs

Case Scenario: When Is Molecular Biomarker Testing Required for Treatment Selection for a B-Cell Malignancy?



“I’m treating a patient with a B-cell malignancy who requires immediate treatment. I understand that the tumor type necessitates molecular biomarker testing to select the best therapy, but how do I choose the right tests, order them, and interpret the results?”

– **Community Oncologist**

Helpful Steps and Considerations

- ✓ **Review Clinical Practice Guidelines** – utilize clinical practice guidelines as a starting point for selecting and interpreting molecular biomarker testing
- ✓ **Connect With a Leading Cancer Center** – connect with leading cancer center to obtain access to specialized molecular testing and expertise in test selection and interpretation of results

Summary



- The treatment paradigm for B-cell malignancies is rapidly changing with the availability of newer targeted therapies and cellular immunotherapy, necessitating straightforward and timely access to educational tools
- Several resources and strategies exist to help community physicians incorporate new therapies into their practice including professional societies, medical congresses, and leading cancer center partnerships
- To optimize patient care, several decision making factors (e.g., clinical practice guidelines, patient preference) must be assimilated when incorporating new treatments

Tools and Resources for the Treatment of B-Cell Malignancies



EDUCATION

ACCC – Association of Community Cancer Centers

Provides nationwide member access to ongoing support and educational information relative to new treatments and technologies, public policy changes, and cost-effective care delivery
acc-cancer.org

ASCO – American Society of Clinical Oncology

Provides members with opportunities for collaboration, professional networking, and knowledge exchange in a worldwide oncology community
asco.org

ASH – American Society of Hematology

A global professional society for clinicians and scientists providing research, education, and advocacy resources for blood diseases
hematology.org

COA – Community Oncology Alliance

An organization for community oncology patients and practices with practice and advocacy resources
communityoncology.org

LLS – Leukemia and Lymphoma Society

A nonprofit that funds blood cancer research and provides disease support and educational resources for both patients and healthcare professionals
lls.org

NCCN – National Comprehensive Cancer Network®

Not-for-profit alliance of 33 leading cancer centers focused on patient care, research, and education; provides clinical practices guidelines in oncology (NCCN Guidelines®)
nccn.org

COMMUNICATION

ADVOCACY